Wells Fargo initiated coverage on aTyr Pharma with a new price target
$ATYR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Wells Fargo initiated coverage of aTyr Pharma with a rating of Overweight and set a new price target of $17.00